Ariad Pharmaceuticals Inc fka ARIA

[biotech_researcher]

Thanks Jess, that was very informative. What caught my eye was this:

The upcoming patent expiries of Novartis´ Gleevec and Bristol-Myers Squibb´s Sprycel will significantly disturb the global sales of CML therapeutics over the next decade. Revenue for Gleevec, which accounted for roughly half of the worldwide CML market value in 2012, is expected to plummet from $1.57 billion in 2012 to $253m in 2022, while Sprycel sales are forecast to drop from $765m to $214m during the same period.

When does Sprycel go generic?